Receptor tyrosine kinases as rational targets for prostate cancer treatment: Platelet-derived growth factor receptor and imatinib mesylate - Discussion

被引：0
|
作者：
Sartor, O
George, DJ
Balk, SP
Johnson, CS
Carroll, PR
Oh, WK
Kantoff, PW
机构：
来源：
UROLOGY | 2002年 / 60卷 / 3A期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：122 / 122
页数：1
相关论文
共 50 条
  • [1] Receptor tyrosine kinases as rational targets for prostate cancer treatment: Platelet-derived growth factor receptor and imatinib mesylate
    George, DJ
    UROLOGY, 2002, 60 (3A) : 115 - 121
  • [2] Combination docetaxel and platelet-derived growth factor receptor inhibition with imatinib mesylate in prostate cancer
    Mathew, P
    Fidler, IJ
    Logothetis, CJ
    SEMINARS IN ONCOLOGY, 2004, 31 (02) : 24 - 29
  • [3] Expression of the platelet-derived growth factor receptor in prostate cancer and treatment implications with tyrosine kinase inhibitors
    Hofer, MD
    Fecko, A
    Shen, RL
    Setlur, SR
    Pienta, KG
    Tomlins, SA
    Chinnaiyan, AM
    Rubin, MA
    NEOPLASIA, 2004, 6 (05): : 503 - 512
  • [4] Imatinib and prostate cancer: lessons learned from targeting the platelet-derived growth factor receptor
    Rosenberg, Aaron
    Mathew, Paul
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2013, 22 (06) : 787 - 794
  • [5] Expression of epidermal growth factor receptor and platelet-derived growth factor receptor in prostate cancer
    Jeong, CW
    Kwak, C
    Lee, SE
    JOURNAL OF UROLOGY, 2006, 175 (04): : 87 - 88
  • [6] Imatinib mesylate treatment for platelet-derived growth factor receptor alfa-positive choroid plexus carcinoma
    Kawakami, Chihiro
    Inoue, Akiko
    Takitani, Kimitaka
    Tsuji, Motomu
    Wakai, Kimiko
    Tamai, Hiroshi
    CLINICS AND PRACTICE, 2012, 2 (02)
  • [7] Expression of the platelet-derived growth factor receptor in prostate cancer and treatment implications with tyrosine kinase inhibitors.
    Hofer, MD
    Fecko, A
    Shen, R
    Setlur, SR
    Pienta, KG
    Tomlins, S
    Chinnaiyan, AM
    Rubin, MA
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6123S - 6123S
  • [8] Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: A modular phase I trial in androgen-independent prostate cancer
    Hofer, MD
    Rubin, MA
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (06) : 1332 - 1333
  • [9] Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: A modular phase I trial in androgen-independent prostate cancer
    Mathew, P
    Thall, PF
    Jones, D
    Perez, C
    Bucana, C
    Troncoso, P
    Kim, SJ
    Fidler, IJ
    Logothetis, C
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (16) : 3323 - 3329
  • [10] Small molecule inhibitors of the platelet-derived growth factor receptor, the fibroblast growth factor receptor, and Src family tyrosine kinases
    Showalter, HDH
    Kraker, AJ
    PHARMACOLOGY & THERAPEUTICS, 1997, 76 (1-3) : 55 - 71
12345